Selinexor/Bortezomib/Dexamethasone Effective for Relapsed/Refractory Multiple Myeloma

In patients with multiple myeloma who have received one to three previous therapies, selinexor/bortezomib/dexamethasone (SVd) significantly improves outcomes compared with bortezomib/dexamethasone (Vd) alone, according to results of the phase 3 BOSTON trial to be presented this week in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.The trial enrolled 402 patients with multiple myeloma who had received one to three prior therapies. Patients were stratified based ...
Continue reading

COVID-19 Outcomes in Patients With Cancer: Miao Liu, MD, PhD

Patients with cancer face unique challenges in the midst of the COVID-19 pandemic: not only do they have an increased risk of contracting COVID-19 in hospital settings, but they also experience more severe clinical outcomes from the disease compared with patients without cancer. In this interview with i3 Health, Miao Liu, MD, PhD, one of the investigators who recently reported these findings in Cancer Discovery, discusses the difficult challenges that patients with cancer face as they continue t...
Continue reading

Daratumumab and Hyaluronidase-fihj FDA Approved for Multiple Myeloma

Daratumumab and hyaluronidase-fihj (Darzalex Faspro™, Janssen Biotech, Inc.) has been approved by the FDA and allows for subcutaneous dosing of daratumumab for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. Previously, intravenous daratumumab was approved for the following indications for patients with multiple myeloma: in combination with bortezomib, melphalan, and prednisone, in combination with lenalidomide and dexamethasone, in combination with bortezomib and de...
Continue reading

Multiple Myeloma, Vitamin D Deficiency, and Race

In patients with multiple myeloma, vitamin D deficiency negatively impacts overall survival in white patients but not in African American patients.Multiple myeloma is a hematologic malignancy that affects plasma cells in the bone marrow, causing damage to the immune system, surrounding organs, and bones. Because vitamin D plays a crucial role in bone health, maintaining an appropriate level of this vitamin is particularly important for patients with multiple myeloma. However, little research had...
Continue reading

Ibrutinib/Rituximab FDA Approved: Treatment-Naive CLL/SLL

Today, the FDA expanded the approval of ibrutinib (Imbruvica®, Pharmacyclics LLC) to include combination therapy with rituximab for the first-line treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Ibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, has previously been approved for treatment-naive CLL in combination with obinutuzumab.The new approval was based on the Eastern Cooperative Oncology Group (ECOG) E1912 trial (NCT02048813), a mult...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.